Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Left Coast Marketing & Design is proud to announce the much anticipated launch of BottleShots.ai, the first SaaS ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Following that, we have some lifestyle images to show you. These come from Samsung itself, as the company has a tendency to release such images with every major launch. The Galaxy S series launch ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Since 1874, Bickford’s has provided Australians with their signature Lime Juice Cordial. You can quickly get their array of thirst-quenching products from Woolworth’s as well. Bondi is not just a ...

Anonymous image hosting can be important when wanting ... Why you can trust TechRadar We spend hours testing every product or service we review, so you can be sure you’re buying the best.

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...